What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
- Main trialPhase 2
- “The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).”In the company’s words, NCT06998043 on ClinicalTrials.gov
Other drugs for Cystic Fibrosis (CF)
- ELX/TEZ/IVAVertex Pharmaceuticals · Phase 3
- IvacaftorVertex Pharmaceuticals · Phase 3
- VNZ/TEZ/D-IVAVertex Pharmaceuticals · Phase 3
- RCT2100ReCode Therapeutics · Phase 2
- SP-101Spirovant Sciences, Inc. · Phase 1/2
- 4D-7104D Molecular Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2026 | Study With Phage for CF Subjects With Pseudomonas Lung Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026